Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care
- 769 Downloads
Raf-mitogen-activated protein kinase (Raf-MAPK) pathway inhibition with the BRAF inhibitors vemurafenib and dabrafenib, alone or in combination with a MEK inhibitor, has become a standard therapeutic approach in patients with BRAF-mutated metastatic melanoma. Both vemurafenib and dabrafenib have shown good safety and efficacy as monotherapy compared with chemotherapy. However, the duration of response is limited in the majority of patients treated with BRAF inhibitor monotherapy because of the development of acquired resistance. The addition of a MEK inhibitor can improve blockade of the MAPK pathway and may help to overcome resistance and thereby prolong efficacy, as well as reduce cutaneous toxicity. Combinations of BRAF inhibitors and MEK inhibitors (dabrafenib plus trametinib and vemurafenib plus cobimetinib) have been approved for the treatment of BRAF-mutant metastatic melanoma and may become a new standard of care. However, acquired resistance is still a significant concern with BRAF and MEK inhibitor combination therapy, and other strategies are being investigated, including the use of sequential and intermittent schedules. The combination of BRAF or MEK inhibitors with immunotherapy has been shown to hold considerable promise, with several combinations being evaluated in clinical trials. Preliminary results from clinical trials involving triple combination therapy with BRAF-MEK inhibitors and anti-PD-L1 antibodies appear promising and may indicate a new strategy to treat patients with BRAF-mutated metastatic melanoma. Biomarkers are needed to help identify patients with BRAFV600 mutations most likely to benefit from first-line BRAF/MEK inhibitor therapy rather than immunotherapy and vice versa.
KeywordsOverall Survival Brain Metastasis Median Overall Survival Ipilimumab Vemurafenib
The authors extend special thanks to Alessandra Trocino for providing excellent bibliography service and assistance.
ES and PAA prepared the manuscript collaboratively with input from and the approval of all co-authors. All authors read and approved the final manuscript.
Compliance with Ethical Standards
No funding was received for the preparation of this review.
Conflict of interest
ES has participated on an advisory board for Bristol Myers Squibb (BMS) and received honoraria from BMS and Novartis. AMG has participated on an advisory board for Novartis and received honoraria from BMS and Novartis. PAA has had consultant and advisory roles for BMS, Merck Sharp & Dohme, Roche-Genentech, Novartis, Amgen, Array, and Merck-Serono. He has received research funds from BMS, Roche-Genentech, and Array. LF, VV, and MP have no conflicts of interest.
- 8.Daud A, Weber J, Sosman J, et al. Updated overall survival (OS) results for BRF113220, a phase I–II study of dabrafenib alone versus combined dabrafenib and trametinib in patients with BRAF V600 metastatic melanoma (MM). J Clin Oncol. 2015;33(Suppl):Abstract 9036.Google Scholar
- 10.Schadendorf D, Amonkar MM, Stroyakoversuskiy D, et al. Health-related quality of life impact in a randomized phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. Eur J Cancer. 2015;51:833–40.CrossRefPubMedGoogle Scholar
- 12.Flaherty KT, Davies MA, Grob J, et al. Genomic analysis and 3-year efficacy and safety update of COMBI-d. J Clin Oncol. 2016;34(Suppl):abstract 9502.Google Scholar
- 13.Grob JJ, Amonkar MM, Karaszewska B, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomized trial. Lancet Oncol. 2015;16:1389–98.CrossRefPubMedGoogle Scholar
- 14.Robert C, Karaszewska B, Schachter J, et al. Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib and trametinib versus vemurafenib as first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. Presented at European Cancer Congress, 2015 Sept 25–29, Vienna. Abstract 3301. http://www.ecco-org.eu/Vienna2015/Scientific-Programme/Searchable-Programme?trackid=00181#anchorScpr. Accessed 29 Sept 2014.
- 17.Pavlick A, Ribas A, Gonzalez R, et al. Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF-mutant melanoma. J Clin Oncol. 2015;33(Suppl):Abstract 9020.Google Scholar
- 19.McArthur GA, Dréno B, Atkinson V, et al. Efficacy of long-term cobimetinib combined with vemurafenib in advanced BRAFV600-mutated melanoma: 3-year follow-up of the phase 3 CoBRIM study and 4-year follow-up of the phase 1b BRIM7 study. Presented at the Society for Melanoma Research 2016 Congress, 2016 Nov 6–9, Boston (MA).Google Scholar
- 20.Sullivan R, Weber J, Patel S, et al. A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment. J Clin Oncol. 2015;33(Suppl):abstract 9007.Google Scholar
- 21.Dummer R, Ascierto PA, Gogas HJ, et al. Results of COLUMBUS Part 1: a phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in BRAF-mutant melanoma. Presented at the Society for Melanoma Research 2016 Congress, 2016 Nov 6–9, Boston (MA).Google Scholar
- 24.Mateus C, Routier E, Roy S, et al. Biomarker study evaluating the combination of dabrafenib (D) with trametinib (T) versus the combination after 8 weeks of monotherapy with dabrafenib or trametinib in patients with metastatic and unresectable stage IIIC or IV melanoma: GSK study 116613. J Clin Oncol. 2014;32(Suppl):TPS9114.Google Scholar
- 25.Algazi A, Othus M, Daud A, et al. SWOG S1320: a randomized phase II trial of intermittent versus continuous dosing of dabrafenib and trametinib in BRAFV600E/k mutant melanoma. J Clin Oncol. 2015;33(Suppl):TPS9093.Google Scholar
- 30.Robert C, Schachter J, Long G, et al. The evolution of melanoma resistance reveals therapeutic opportunities. Cancer Res. 2015;73:6106–10.Google Scholar
- 31.Hodi FS, Kluger K, Sznol M, et al. Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial. Presented at AACR Annual Meeting AACR, 2016 Apr 16–20, New Orleans (LA). doi: 10.1158/1538-7445.AM2016-CT001.
- 33.Hodi F, Sznol M, Kluger H, et al. Long-term survival of ipilimumab-naive patients with advanced melanoma treated with nivolumab in a phase I trial. J Clin Oncol. 2014;32(Suppl):abstract 9002.Google Scholar
- 36.Hamid O, Patel M, Hodi S, et al. Preliminary clinical safety, tolerability and activity of atezolizumab (anti-PDL1) combined with vemurafenib in BRAFV600 metastatic melanoma. Pigment Cell Melanoma Res. 2015;28(6):778 (abstract). doi: 10.1111/pcmr.12419.
- 37.Sullivan RJ, Hamid O, Gonzalez R, et al. Safety and clinical activity of atezolizumab + cobimetinib + vemurafenib in BRAFV600-mutant metastatic melanoma. Presented at the Society for Melanoma Research 2016 Congress, 2016 Nov 6–9, Boston (MA). https://www.melanomacongress.com/docs/2016_abstracts.pdf.
- 39.Ribas A, Butler M, Lutzky J, et al. Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. J Clin Oncol. 2015;33(Suppl):Abstract 3003.Google Scholar
- 40.Ribas A, Hodi FS, Lawrence DP, et al. Pembrolizumab in combination with dabrafenib and trametinib for B-RAF mutant advanced melanoma: Phase I Keynote-022 study. J Clin Oncol. 2016;34(Suppl):Abstract 3014.Google Scholar
- 46.Daud A, Ribas A, Robert C, et al. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. J Clin Oncol. 2015;33(Suppl):Abstract 9005.Google Scholar
- 51.McArthur GA, Larkin JM, Ascierto PA, et al. Efficacy of cobimetinib and vemurafenib in patients with advanced BRAF-mutated melanoma with poor and favorable prognosis in the coBRIM phase 3 study. J Clin Oncol. 2016;34(Suppl):Abstract 9350.Google Scholar
- 54.Wongchenko MJ, Ribas A, Dréno B, et al. Progression-free and overall survival with cobimetinib (cobi) + vemurafenib (vem) + treatment is independent of PD-L1 expression. Presented at the Society for Melanoma Research 2016 Congress, 2016 Nov 6–9, Boston (MA). https://www.melanomacongress.com/docs/2016_abstracts.pdf.
- 60.Ribas A, Robert C, Hodi FS, et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. J Clin Oncol. 2013;33(Suppl):Abstract 3001.Google Scholar
- 61.Yan Y, Robert C, Larkin J, et al. Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone. Ann Oncol. 2016;27(Suppl 6):1111O.Google Scholar
- 64.Mittapalli R, Vaidhyanathan S, Dudek A, Elmquist W. Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther. 2013;344:655–64.CrossRefPubMedPubMedCentralGoogle Scholar
- 67.Kefford R, Malo M, Arance A, et al. Vemurafenib in metastatic melanoma patients with brain metastases: an open label, single arm, phase 2, multicenter study. Presented at 2013 Society for Melanoma Research Congress, 2013 Nov 17–20, Philadelphia (PA).Google Scholar
- 68.Queirolo P, Spagnolo F, Picasso V, et al. Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib. Oncotarget. 2016. doi: 10.18632/oncotarget.10589.
- 69.Davies M, Martins K, Sessa T, Swann S. Phase II, open-label study of dabrafenib plus trametinib in patients with BRAF mutation-positive melanoma brain metastases: a GSK-sponsored trial. J Clin Oncol. 2014;32(Suppl):TPS9106.Google Scholar
- 70.Yee M, Lin Y, Gorantla V, et al. Phase 2 study of cobimetinib in combination with vemurafenib in active melanoma brain metastases (coBRIM-B). J Clin Oncol. 2015;33(Suppl):TPS9088.Google Scholar